ABSTRACT
Background: In patients with hematologic malignancies response to Covid-19-vaccination is unpredictable because these patients were excluded from clinical trials in the past. Method(s): We measured B-cell-response by means of Covid-S1-antibody reaction (SARS-CoV-2 IgG, Siemens Atellica IM) at earliest 3 weeks after second vaccination with the BNT162b2. In some patients T-cell-response is determined by a Covid-Quantiferon-test (QuantiFERON SARS-CoV-2, Qiagen) Result: Untill August 2021 results for Covid-S1-antibody-testing were present in 89 patients. In 46 of these patients response to vaccination was missing by means of antibody determination (no measurable antibodies against S1-antigen). Patients with no response to vaccination were mainly patients with B-cell-lymphoma but also patients with multiple myeloma und chronic myelomonocytic leukemia. 56 of 89 patients were on or after therapy with CD20-antibodies, respectivley. 39 of these 56 Patients had no response to vaccination. Discussion(s): Most available data concerning response to vaccination against Covid-19-virus in patients with hematologic malignancies relate to chronic B-cell leukemia and Covid-S1-antibody response. We present single institution data of a variety of malignant hematologic diseases and evalutate T-cell-response additionally. Conclusion(s): Patients with hematologic malignancies and treatment with CD20-abtibodies have a very high risk not to respond to vaccination against Covid-19-virus. Since vaccination and testing has not finished yet in our patients we will present updated results on response to vaccination with respect to hematologic diagnosis, total dose of and intervall to CD20- antibody-therapy on DKK-meeting in 2022.